Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration

ConclusionsWeekly, oral ONC201 is well-tolerated and results in enhanced immunostimulatory activity that warrants further investigation.Trial registrationNCT02250781 (Oral ONC201 in Treating Patients With Advanced Solid Tumors),NCT02324621 (Continuation of Oral ONC201 in Treating Patients With Advanced Solid Tumors).
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research